New inhibitor targeting Acyl-CoA synthetase 4 reduces breast and prostate tumor growth, therapeutic resistance and steroidogenesis
- Castillo, Ana Fernanda
- Orlando, Ulises Daniel
- Maloberti, Paula Mariana
- Prada, Jesica Giselle
- Dattilo, Melina Andrea
- Solano, Angela Rosario
- Bigi, Maria de Las Mercedes
- Ríos Medrano, Mayra Agustina
- Torres, María T.
- Indo, Sebastián
- Caroca, Graciela
- Contreras, Hector R.
- Marelli, Belkis Ester
- Salinas, Facundo José
- Salvetti, Natalia Raquel
- Ortega, Hugo Hector
- Lorenzano Menna, Pablo
- Szajnman, Sergio Hernan
- Gómez, Daniel Eduardo
- Rodriguez, Juan Bautista
- Podesta, Ernesto Jorge
DOIAbstract
Acyl-CoA synthetase 4 (ACSL4) is an isoenzyme of the fatty acid ligase-coenzyme-A family taking part in arachidonic acid metabolism and steroidogenesis. ACSL4 is involved in the development of tumor aggressiveness in breast and prostate tumors through the regulation of various signal transduction pathways. Here, a bioinformatics analysis shows that the ACSL4 gene expression and proteomic signatures obtained using a cell model was also observed in tumor samples from breast and cancer patients. A well-validated ACSL4 inhibitor, however, has not been reported hindering the full exploration of this promising target and its therapeutic application on cancer and steroidogenesis inhibition. In this study, ACSL4 inhibitor PRGL493 was identified usi...
Add to ORKG